ストックスクリーナーアプリを入手
0.73
2.82%
0.02
アフターアワーズ：
.73
前日終値:
$0.71
開ける：
$0.75
24時間の取引高:
826
Relative Volume:
8.99
時価総額：
$N/A
収益：
-
当期純損益:
$-22.01M
株価収益率:
-0.00855
EPS:
-85.4
ネットキャッシュフロー:
$-18.31M
1週間 パフォーマンス:
+2.82%
1か月 パフォーマンス:
-21.06%
6か月 パフォーマンス:
-81.55%
1年 パフォーマンス:
-88.61%
1日の値動き範囲:
$0.60
$0.75
1週間の範囲:
$0.60
$0.75
52週間の値動き範囲:
$0.60
$0.9389
Vaccinex Inc Stock (VCNX) Company Profile
VCNX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VCNX
Vaccinex Inc
|
0.73 | 0 | 0 | -22.01M | -18.31M | -85.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.20 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
525.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.09 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
551.22 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Vaccinex Inc Stock (VCNX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-09-23 | ダウングレード | BTIG Research | Buy → Neutral |
| 2018-09-04 | 開始されました | Ladenburg Thalmann | Buy |
Vaccinex Inc (VCNX) 最新ニュース
Vaccinex (NASDAQ:VCNX) Shares Down 2.4% – Time to Sell? - Defense World
Vaccinex presents promising cancer treatment data at ASCO By Investing.com - Investing.com India
Vaccinex to Report Promising New Clinical Results of Neoadjuvant - GuruFocus
Vaccinex presents promising cancer treatment data at ASCO - Investing.com
Vaccinex, Inc. to Present New Data on Pepinemab's Role in Enhancing Immune Responses in Head and Neck Cancer at ASCO 2025 - Nasdaq
Vaccinex to Report Promising New Clinical Results of - GlobeNewswire
Clinical Trial Success: New Drug Transforms Cold Tumors into Hot Immune Centers in Head and Neck Cancer - Stock Titan
Vaccinex (NASDAQ:VCNX) Stock Price Down 11.3% – Here’s What Happened - Defense World
AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets - ACCESS Newswire
Vaccinex (NASDAQ:VCNX) Trading 9.9% Higher – Still a Buy? - Defense World
Vaccinex reports pepinemab boosts immune response in cancer By Investing.com - Investing.com South Africa
Vaccinex (VCNX) Presents New Findings on Pepinemab for Cancer Tr - GuruFocus
Vaccinex to Report Promising New Clinical Data Revealing Pepinem - GuruFocus
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR) | VCNX Stock News - GuruFocus
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR) - The Manila Times
Vaccinex reports pepinemab boosts immune response in cancer - Investing.com Australia
Vaccinex, Inc. Announces Promising Data on Pepinemab as Neoadjuvant Immunotherapy in Metastatic Melanoma and Head and Neck Cancer at AACR 2025 - Nasdaq
Vaccinex to Report Promising New Clinical Data Revealing - GlobeNewswire
VACCINEX, INC. SEC 10-K Report - TradingView
Pre-market Movers In Healthcare Sector: CTXR, VCNX, SRNE, ITRM, RWLK… - RTTNews
Osteosarcoma Market Set for Groundbreaking Expansion by 2032, Forecasts DelveInsight | Aurora Biopharma, BioAtla, Iovance Biotherapeutics, Isofol Medical AB, Bristol-Myers Squibb, Cellestia Biotech - The Globe and Mail
Vaccinex Delays Yearly Report Filing - TipRanks
Vaccinex director resigns, no disagreement cited By Investing.com - Investing.com South Africa
Vaccinex director resigns, no disagreement cited - Investing.com India
Stocks in play: Neo Performance Materials Inc. - The Globe and Mail
Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - Citeline News & Insights
Vaccinex plans Nasdaq exit as Alzheimer market pressure grows - Yahoo Finance
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market - GlobeNewswire
Can Vaccinex Survive After Nasdaq Exit? Key Details on Company's Future Strategy - StockTitan
Vaccinex Stock Price, Quotes and Forecasts | OTC:VCNX - Benzinga
Vaccinex (NASDAQ:VCNX) Stock Price Down 3.7% – Time to Sell? - Defense World
Alzheimer's Disease Clinical Trial Pipeline | 110+ Companies Pioneering Breakthroughs in Treatment | - EIN News
RFK Jr. says he's resigned from anti-vaccine nonprofit as he seeks nation's top health official job - AP News
Vaccinex (NASDAQ:VCNX) Stock Price Down 3.4% – What’s Next? - Defense World
Louisiana forbids public health workers from promoting COVID, flu and mpox shots : ShotsHealth News - NPR
Vaccinex Faces Delisting from Nasdaq, Details Plans for OTC Quotation - Defense World
United States shares lower at close of trade; Dow Jones Industrial Average down 0.61% - Investing.com India
Vaccinex stock plunges to 52-week low at $1.36 amid market challenges - Investing.com
Vaccinex Stock to Be Delisted From Nasdaq - Marketscreener.com
Vaccinex to be delisted from Nasdaq over equity shortfall - Investing.com
Vaccinex, Inc. (NASDAQ:VCNX) Sees Large Decline in Short Interest - Defense World
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
SIMM Launches WNY Stock Index - The Bona Venture
Vaccinex Inc (VCNX) Quarterly 10-Q Report - Quartz
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - PR Newswire
Pre-market Movers: REVB, CDIO, SMLR, DWTX... - RTTNews
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC - GlobeNewswire
Vaccinex's Pepinemab Breakthrough: New Data Shows Enhanced Cancer Immunotherapy Success - StockTitan
Vaccinex reports progress in Alzheimer's treatment study By Investing.com - Investing.com Australia
Capricor Therapeutics (CAPR) Faces 5% Drop Amid Industry Slump - GuruFocus.com
Vaccinex Inc (VCNX) 財務データ
収益
当期純利益
現金流量
EPS
0.78%
0.23%
大文字化:
|
ボリューム (24 時間):